HLSQ

SEC source: 0001213900-23-095417 · ownership.xml · derivative · entry 4

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-03-30

F3 · kind: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 152,000 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 40,000 shares, having an exercise price of $0.2749 per share.

F3 · price: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 152,000 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 40,000 shares, having an exercise price of $0.2749 per share.

F4 · derivative.exercise_date: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

SEC source: 0001213900-23-095417 · ownership.xml · derivative · entry 3

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 152,000 shares

Expires 2031-03-30

F3 · kind: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 152,000 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 40,000 shares, having an exercise price of $0.2749 per share.

F3 · price: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 152,000 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 40,000 shares, having an exercise price of $0.2749 per share.

F4 · derivative.exercise_date: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

SEC source: 0001213900-23-095417 · ownership.xml · derivative · entry 2

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,895

Underlying: Common Stock · 37,895 shares

Expires 2030-03-25

F1 · kind: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 144,000 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 37,895 shares, having an exercise price of $0.2749 per share.

F1 · price: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 144,000 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 37,895 shares, having an exercise price of $0.2749 per share.

F2 · derivative.exercise_date: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 25, 2021, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

SEC source: 0001213900-23-095417 · ownership.xml · derivative · entry 1

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 144,000 shares

Expires 2030-03-25

F1 · kind: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 144,000 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 37,895 shares, having an exercise price of $0.2749 per share.

F1 · price: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 144,000 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 37,895 shares, having an exercise price of $0.2749 per share.

F2 · derivative.exercise_date: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 25, 2021, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

SEC source: 0001213900-23-095415 · ownership.xml · derivative · entry 4

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,750

Underlying: Common Stock · 8,750 shares

Expires 2031-03-30

F3 · kind: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 33,250 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 8,750 shares, having an exercise price of $0.2749 per share.

F3 · price: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 33,250 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 8,750 shares, having an exercise price of $0.2749 per share.

F4 · derivative.exercise_date: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

SEC source: 0001213900-23-095415 · ownership.xml · derivative · entry 3

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,250 shares

Expires 2031-03-30

F3 · kind: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 33,250 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 8,750 shares, having an exercise price of $0.2749 per share.

F3 · price: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 33,250 shares of the Issuer's common stock granted to the Reporting Person on March 30, 2021. In exchange, the Reporting Person received a replacement option, for 8,750 shares, having an exercise price of $0.2749 per share.

F4 · derivative.exercise_date: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 30, 2022, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

SEC source: 0001213900-23-095415 · ownership.xml · derivative · entry 2

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,290

Underlying: Common Stock · 8,290 shares

Expires 2030-03-25

F1 · kind: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 31,500 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 8,290 shares, having an exercise price of $0.2749 per share.

F1 · price: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 31,500 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 8,290 shares, having an exercise price of $0.2749 per share.

F2 · derivative.exercise_date: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 25, 2021, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

SEC source: 0001213900-23-095415 · ownership.xml · derivative · entry 1

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,500 shares

Expires 2030-03-25

F1 · kind: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 31,500 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 8,290 shares, having an exercise price of $0.2749 per share.

F1 · price: On December 11, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, an option for 31,500 shares of the Issuer's common stock granted to the Reporting Person on March 25, 2020. In exchange, the Reporting Person received a replacement option, for 8,290 shares, having an exercise price of $0.2749 per share.

F2 · derivative.exercise_date: The cancelled option provided for vesting over four years, with 25% of the shares subject to the option vested on March 25, 2021, and the remainder vested in 12 equal quarterly installments over three years. The replacement option vests according to the same vesting schedule applicable to the cancelled option; provided, however, that the replacement option may not be exercised prior to December 11, 2024.

SEC source: 0001213900-23-092074 · ownership.xml · nonDerivative · entry 3

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001213900-23-092074 · ownership.xml · nonDerivative · entry 2

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,056

SEC source: 0001213900-23-092074 · ownership.xml · nonDerivative · entry 1

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,470

SEC source: 0001213900-23-081868 · ownership.xml · derivative · entry 2

Bassan Merav · CIK 0001792702 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2029-10-10

F1 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 10/10/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 10/10/2020, and the remainder vesting in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 10/10/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 10/10/2020, and the remainder vesting in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081868 · ownership.xml · derivative · entry 1

Bassan Merav · CIK 0001792702 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2029-10-10

F1 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 10/10/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 10/10/2020, and the remainder vesting in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 10/10/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 10/10/2020, and the remainder vesting in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081861 · ownership.xml · derivative · entry 1

Wolfson Marina · CIK 0001797360 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,800

Underlying: Common Stock · 0 shares

Expires 2033-10-29

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on October 29, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-081860 · ownership.xml · derivative · entry 6

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2029-03-29

F3 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081860 · ownership.xml · derivative · entry 5

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2029-03-29

F3 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081860 · ownership.xml · derivative · entry 4

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2028-05-22

F2 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provided for vesting over four years, with 25% of the shares subject to the option vesting on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provided for vesting over four years, with 25% of the shares subject to the option vesting on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081860 · ownership.xml · derivative · entry 3

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2028-05-22

F2 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provided for vesting over four years, with 25% of the shares subject to the option vesting on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provided for vesting over four years, with 25% of the shares subject to the option vesting on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081860 · ownership.xml · derivative · entry 2

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2027-03-26

F1 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provided for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provided for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081860 · ownership.xml · derivative · entry 1

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2027-03-26

F1 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provided for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provided for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081857 · ownership.xml · derivative · entry 6

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2029-03-29

F3 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081857 · ownership.xml · derivative · entry 5

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2029-03-29

F3 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F3 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081857 · ownership.xml · derivative · entry 4

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2028-05-22

F2 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provides for vesting over four years, with 25% of the shares subject to the option vested on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provides for vesting over four years, with 25% of the shares subject to the option vested on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081857 · ownership.xml · derivative · entry 3

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2028-05-22

F2 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provides for vesting over four years, with 25% of the shares subject to the option vested on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provides for vesting over four years, with 25% of the shares subject to the option vested on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081857 · ownership.xml · derivative · entry 2

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2027-03-26

F1 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001213900-23-081857 · ownership.xml · derivative · entry 1

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2027-03-26

F1 · kind: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.

SEC source: 0001013762-23-005831 · ownership.xml · derivative · entry 1

Williams Eddie · CIK 0001725276 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 0 shares

Expires 2033-10-19

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on October 19, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-070256 · ownership.xml · derivative · entry 1

Marks Jason M. · CIK 0001878953 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 0 shares

Expires 2033-08-21

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on August 21, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-070255 · ownership.xml · derivative · entry 1

Dambach Michael E. · CIK 0001977134 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 0 shares

Expires 2033-08-21

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on August 21, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-042514 · ownership.xml · nonDerivative · entry 1

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,914

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.27 to $0.28, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.

SEC source: 0001213900-23-041960 · ownership.xml · nonDerivative · entry 2

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,722

F2 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.2752 to $0.2898, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.

SEC source: 0001213900-23-041960 · ownership.xml · nonDerivative · entry 1

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,201

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.2701 to $0.2750, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.

SEC source: 0001213900-23-017221 · ownership.xml · derivative · entry 1

Greig Russell · CIK 0001789914 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Common Stock · 82,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-017212 · ownership.xml · derivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 41,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-017218 · ownership.xml · derivative · entry 1

Moses Alan Charles · CIK 0001819501 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,000

Underlying: Common Stock · 41,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-017217 · ownership.xml · derivative · entry 1

Bassan Merav · CIK 0001792702 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-017216 · ownership.xml · derivative · entry 1

Wolfson Marina · CIK 0001797360 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-017209 · ownership.xml · derivative · entry 1

Solomon Jonathan Eitan · CIK 0001792322 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 410,000

Underlying: Common Stock · 410,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0001213900-23-017206 · ownership.xml · derivative · entry 1

Oron Assaf · CIK 0001792310 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-03-01

F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 1, 2024, and the remainder vesting in 12 equal quarterly installments over three years.

SEC source: 0000947871-23-000336 · ownership.xml · derivative · entry 2

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · 10% owner

GORDON CARL L · CIK 0001282930 · 10% owner

Chimovits Erez · CIK 0001706399 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,789,959

Underlying: Common Stock · 1,789,959 shares

Expires 2033-02-27

F1 · price: These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants.

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.

F3 · ownership.nature: Each of OrbiMed Israel, OrbiMed BioFund, Carl Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-23-000336 · ownership.xml · nonDerivative · entry 1

OrbiMed Israel BioFund GP Limited Partnership · CIK 0001569821 · 10% owner

OrbiMed Israel GP Ltd. · CIK 0001569590 · 10% owner

GORDON CARL L · CIK 0001282930 · 10% owner

Chimovits Erez · CIK 0001706399 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,161,489

F1 · shares: These shares of the Issuer's common stock and warrants to purchase shares of the Issuer's common stock were purchased from the Issuer in a private placement. The warrants are exercisable for one share of the Issuer's common stock per warrant, subject to an issuance limitation that prohibits the holder from exercising the warrants to the extent that after giving effect to such issuance after exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the Reporting Persons) would beneficially own in excess of 9.99% of the shares of common stock outstanding immediately after giving effect to the issuance of the shares of common stock issuance upon exercise of the warrants.

F2 · ownership.nature: These securities are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon and Erez Chimovits.

F3 · ownership.nature: Each of OrbiMed Israel, OrbiMed BioFund, Carl Gordon, and Erez Chimovits disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 15

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 2,997,025

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 14

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 2,998,526

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 13

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,000,526

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 12

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,002,942

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 11

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,004,242

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 10

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,007,542

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 9

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,009,068

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 8

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,010,573

F1 · balance_after: The shares are directly held by SymBiosis, LLC.

SEC source: 0001014108-22-000163 · primary_doc.xml · nonDerivative · entry 7

Ugwumba Chidozie · CIK 0001835544 · Exit Form 4 - former 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By SymBiosis, LLC

Disclosed balance after: 3,023,073

F1 · balance_after: The shares are directly held by SymBiosis, LLC.